|1.||Zhang, Yahong: 1 article (01/2014)|
|2.||Zhao, Huijun: 1 article (01/2014)|
|3.||Wang, Zhaoyi: 1 article (01/2014)|
|4.||Wang, Jianhong: 1 article (01/2014)|
|5.||Zhao, Jin: 1 article (01/2014)|
|6.||Luo, Zhaoyang: 1 article (01/2014)|
|7.||Kiraly, Alex: 1 article (12/2011)|
|8.||Hacker, Miles: 1 article (12/2011)|
|9.||Gunning, William: 1 article (12/2011)|
|10.||Koffman, Boyd: 1 article (12/2011)|
|1.||Breast Neoplasms (Breast Cancer)
12/01/1991 - "Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer."
06/01/1999 - "Losoxantrone, an anthrapyrazole in clinical development, has shown promising single-agent activity in metastatic breast cancer. "
09/01/1993 - "The anthrapyrazole derivative biantrazole (7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2- hydroxyethyl)amino]ethyl]amino]-anthra[1,9-cd]pyrazol-6(2H)-one dihydrochloride, CI-941) is currently under clinical investigation for the treatment of breast cancer. "
12/01/1991 - "Thirty-one patients with advanced breast cancer were treated with CI941, an anthrapyrazole structurally related to mitoxantrone. "
01/01/1992 - "Taxol, navelbine, and anthrapyrazole CI-941 have been found to have major efficacy against breast cancer, with response rates exceeding 50%. "
07/01/2008 - "In vitro cytotoxic activity of anthrapyrazole analogues in human prostate DU-145 and testicular NTERA-2 carcinoma cells."
06/01/1995 - "A phase II trial of the new anthrapyrazole piroxantrone was conducted by the Southwest Oncology Group in advanced ovarian carcinoma. "
07/01/2008 - "Anthrapyrazoles are potent cytotoxic agents that intercalate into DNA, causing DNA strand breaks, inhibition of DNA synthesis and topoisomerase II. In this study, we investigated the in vitro cytotoxic activity of two anthrapyrazole analogues (AP-10 and AP-11) in human prostate (DU-145) and testicular (NTERA-2) carcinoma cells. "
11/01/1985 - "Because of the high activity of the anthrapyrazole series as a class in the National Cancer Institute tumor panel, additional testing was necessary to allow selection of clinical candidates. "
01/01/2004 - "Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)."
01/01/2014 - "Among them, the polyamine-based anthrapyrazole derivatives 4c and 4f-g showed superior cytotoxicity than that of Mitoxantrone both on cancer cell lines and the drug-resistant subline. "
07/01/1990 - "Pirozantrone hydrochloride, an anthrapyrazole analogue, was selected for clinical evaluation based on broad antitumor activity against murine tumor systems and on potentially less cardiotoxicity when compared to anthracyclines. "
01/01/1989 - "The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients."
|4.||Endometrial Neoplasms (Endometrial Cancer)
|5.||Prostatic Neoplasms (Prostate Cancer)
|5.||DNA (Deoxyribonucleic Acid)
|7.||Type II DNA Topoisomerases (Topoisomerase II)
|10.||Antineoplastic Agents (Antineoplastics)